NCT03454451 2023-12-21CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersCorvus Pharmaceuticals, Inc.Phase 1 Completed117 enrolled
NCT02655822 2021-08-30Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced CancersCorvus Pharmaceuticals, Inc.Phase 1 Completed502 enrolled